 Connection
James Burton to Hepatitis C
This is a "connection" page, showing publications James Burton has written about Hepatitis C.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
2.691 |
|
|
|
-
Nordstrom EM, Biggins SW, Gralla J, Rosen HR, Everson GT, Burton JR. Consensus Interferon for Recurrent Hepatitis C Infection in Nonresponders to Peginterferon and Ribavirin After Liver Transplant. Exp Clin Transplant. 2015 Dec; 13(6):543-9.
Score: 0.426
-
Burton JR, O'Leary JG, Verna EC, Saxena V, Dodge JL, Stravitz RT, Levitsky J, Trotter JF, Everson GT, Brown RS, Terrault NA. A US multicenter study of hepatitis C treatment of liver transplant recipients with protease-inhibitor triple therapy. J Hepatol. 2014 Sep; 61(3):508-14.
Score: 0.382
-
Burton JR, Rosen HR. Acute rejection in HCV-infected liver transplant recipients: The great conundrum. Liver Transpl. 2006 Nov; 12(11 Suppl 2):S38-47.
Score: 0.227
-
Burton JR, Rosen HR. Treatment of HCV recurrence: do the pretransplantation rules apply? Liver Transpl. 2006 Jul; 12(7):1044-8.
Score: 0.222
-
Burton JR, Rosen HR. Liver retransplantation for hepatitis C virus recurrence: a survey of liver transplant programs in the United States. Clin Gastroenterol Hepatol. 2005 Jul; 3(7):700-4.
Score: 0.207
-
Burton JR, Rosen HR. Retransplantation for hepatitis C: what do we really know? Liver Transpl. 2004 Dec; 10(12):1504-6.
Score: 0.199
-
Burton JR, Sonnenberg A, Rosen HR. Retransplantation for recurrent hepatitis C in the MELD era: maximizing utility. Liver Transpl. 2004 Oct; 10(10 Suppl 2):S59-64.
Score: 0.196
-
Terrault NA, Burton J, Ghobrial M, Verna E, Bayer J, Klein C, Victor D, Mohan S, Trotter J, Dodge J, Niemann CU, Rubin RA. Prospective Multicenter Study of Early Antiviral Therapy in Liver and Kidney Transplant Recipients of HCV-Viremic Donors. Hepatology. 2021 06; 73(6):2110-2123.
Score: 0.152
-
O'Leary JG, Fontana RJ, Brown K, Burton JR, Firpi-Morell R, Muir A, O'Brien C, Rabinovitz M, Reddy R, Ryan R, Shprecher A, Villadiego S, Prabhakar A, Brown RS. Efficacy and safety of simeprevir and sofosbuvir with and without ribavirin in subjects with recurrent genotype 1 hepatitis C postorthotopic liver transplant: the randomized GALAXY study. Transpl Int. 2017 Feb; 30(2):196-208.
Score: 0.115
-
Brown RS, O'Leary JG, Reddy KR, Kuo A, Morelli GJ, Burton JR, Stravitz RT, Durand C, Di Bisceglie AM, Kwo P, Frenette CT, Stewart TG, Nelson DR, Fried MW, Terrault NA. Interferon-free therapy for genotype 1 hepatitis C in liver transplant recipients: Real-world experience from the hepatitis C therapeutic registry and research network. Liver Transpl. 2016 Jan; 22(1):24-33.
Score: 0.107
-
Verna EC, Saxena V, Burton JR, O'Leary JG, Dodge JL, Stravitz RT, Levitsky J, Trotter JF, Everson GT, Brown RS, Terrault NA. Telaprevir- and Boceprevir-based Triple Therapy for Hepatitis C in Liver Transplant Recipients With Advanced Recurrent Disease: A Multicenter Study. Transplantation. 2015 Aug; 99(8):1644-51.
Score: 0.104
-
Biggins SW, Trotter J, Gralla J, Burton JR, Bambha KM, Dodge J, Brocato M, Cheng L, McQueen M, Forman L, Chang M, Kam I, Everson G, Spritz RA, Klintmalm G, Rosen HR. Differential effects of donor and recipient IL28B and DDX58 SNPs on severity of HCV after liver transplantation. J Hepatol. 2013 May; 58(5):969-76.
Score: 0.087
-
Smyk-Pearson S, Golden-Mason L, Klarquist J, Burton JR, Tester IA, Wang CC, Culbertson N, Vandenbark AA, Rosen HR. Functional suppression by FoxP3+CD4+CD25(high) regulatory T cells during acute hepatitis C virus infection. J Infect Dis. 2008 Jan 01; 197(1):46-57.
Score: 0.061
-
McCashland T, Watt K, Lyden E, Adams L, Charlton M, Smith AD, McGuire BM, Biggins SW, Neff G, Burton JR, Vargas H, Donovan J, Trotter J, Faust T. Retransplantation for hepatitis C: results of a U.S. multicenter retransplant study. Liver Transpl. 2007 Sep; 13(9):1246-53.
Score: 0.060
-
Rosen HR, Weston SJ, Im K, Yang H, Burton JR, Erlich H, Klarquist J, Belle SH. Selective decrease in hepatitis C virus-specific immunity among African Americans and outcome of antiviral therapy. Hepatology. 2007 Aug; 46(2):350-8.
Score: 0.060
-
Golden-Mason L, Burton JR, Castelblanco N, Klarquist J, Benlloch S, Wang C, Rosen HR. Loss of IL-7 receptor alpha-chain (CD127) expression in acute HCV infection associated with viral persistence. Hepatology. 2006 Nov; 44(5):1098-109.
Score: 0.057
-
MacBrayne CE, Castillo-Mancilla J, Burton JR, MaWhinney S, Wagner CB, Micke K, Fey J, Huntley RT, Larson B, Bushman LR, Kiser JJ. Small increase in dolutegravir trough, but equivalent total dolutegravir exposure with simeprevir in HIV/HCV seronegative volunteers. J Antimicrob Chemother. 2018 Jan 01; 73(1):156-159.
Score: 0.031
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|